Ingen Technologies Inc (IGNT)

[ronsha]

NEWS!!
Ingen China Patent is Now Issued and Published

China is Close Target for Oxyview Nasal Cannula Distribution

YUCAIPA, Calif., Oct 1, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that the Company has received notification from its patent attorney, Donn Harms, regarding the publication of the Chinese patent for the Oxyview and the Oxyview Nasal Cannula.

The designated Chinese patent application no. 200710005067.4 was officially issued and published on July 1, 2009 for the cannula gas flow meter referred to as "Oxyview".

The company's pending patents in Japan, Canada, and the European Communities are expected to issue in 2010.

Donn K. Harms is a Registered Patent Attorney also handling business and corporate law matters since 1988, with heavy emphasis on trademarks, copyrights, patents, and licensing matters. Mr. Harms is certified by the San Diego County Bar Association for trademarks, and is a former member of the American Bar Association Committee on Trademark Law for recommendations to the U.S. Congress. His San Diego based firm, American Patent and Trademark Law Center, is a professional association of independent registered patent attorneys and specializes in patent, trademark, copyright and related business and government contract matters with agents and associates throughout the world, including China and Russia, providing various types of domestic and international filing needs for their clients. The firm is registered to practice before the United States Patent & Trademark Office.

"Mr. Harms has been our patent attorney since 1997, and has effectively provided his services that have allowed for several issued patents, domestic and foreign. You could not find a more successful firm and patent attorney than Donn Harms. Our patents provide a higher valuation of our company and additional security to our intellectual property, specifically our new "gravity-independent" technology applied to the Oxyview products, and our "digital transmission" technology applied to our OxyAlert products. The world market for our products includes 600M patients requiring supplementary oxygen and home oxygen therapy. We have recently shown increased sales in the USA with demand of our Oxyview Nasal Cannula products, and we have the company positioned to enter markets in China, Europe, Japan, Canada and Australia for product distribution in early 2010 as an additional revenue stream for Ingen," stated Scott R. Sand, CEO and Chairman of the Board.

http://www.patentpending.com/